CLAIMS:

1. A monoclonal antibody or an antigen-binding portion thereof that specifically binds to a filovirus, wherein the antibody or antigen-binding portion thereof comprises (i) an immunoglobulin light chain variable region comprising LCDR1, LCDR2, and LCDR3, and (ii) an immunoglobulin heavy chain variable region comprising HCDR1, HCDR2, and HCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs: 6, 7, and 8, respectively, and the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs: 18, 19, and 20, respectively.

2. The monoclonal antibody or antigen-binding portion thereof of claim 1, wherein the immunoglobulin light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:2 and the immunoglobulin heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:14.

3. The monoclonal antibody or antigen-binding portion thereof of claim 1 or 2, wherein the monoclonal antibody or antigen-binding portion thereof is selected from the group consisting of: (i) a whole immunoglobulin molecule; (b) an scFv; (c) a Fab fragment; (d) an $F(ab')_2$; and (e) a disulfide linked Fv.

4. The monoclonal antibody of any one of claims 1-3, wherein the antibody comprises an immunoglobulin constant region selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, and IgM.

5. The monoclonal antibody or antigen-binding portion thereof of any one of claims 1-4, wherein the filovirus is a member of the *Marburgvirus* genus.

6. The monoclonal antibody or antigen-binding portion thereof of claim 5, wherein the filovirus is selected from the group consisting of Ravn, Angola, Musoke, and Popp Marburg virus strains.

7. The monoclonal antibody or antigen-binding portion thereof of any one of claims 1-6, wherein the monoclonal antibody or antigen-binding portion binds to the Marburg virus glycoprotein.

8. The monoclonal antibody or antigen-binding portion thereof of any one of claims 1-7, wherein the monoclonal antibody or antigen-binding portion thereof binds to the GP2 subunit of the Marburg virus glycoprotein.

9. A pharmaceutical composition comprising the monoclonal antibody or antigen-binding portion thereof of any one of claim 1-8 and at least one pharmaceutically acceptable adjuvant.

10. A pharmaceutical composition comprising the monoclonal antibody or antigen-binding portion thereof of any one of claims 1-8 and at least one pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 9 or 10, further comprising a second agent.

12. The pharmaceutical composition of claim 11, wherein the second agent is a monoclonal antibody or antigen-binding portion thereof.

13. The pharmaceutical composition of claim 11 or 12, wherein the pharmaceutical composition comprises at least one Marburg virus-binding antibody or antigen-binding portion thereof, and at least one Ebola virus-binding antibody or antigen-binding portion thereof.

14. The pharmaceutical composition of any one of claims 9-13, wherein the pharmaceutical composition comprises at least two, at least three, or at least four Marburg virus-binding antibodies or antigen-binding portion thereof.

15. The pharmaceutical composition of any one of claims 9-14, wherein the pharmaceutical composition comprises at least two Marburg virus-binding antibodies or antigen-binding portion thereof, and wherein each Marburg virus-binding antibody or antigen-binding portion thereof binds to a different epitope of the Marburg virus glycoprotein.

16. Use of the monoclonal antibody or antigen-binding portion thereof of any one of claims 1-8 or the pharmaceutical composition of any one of claims 9-15 in the preparation of a medicament for ameliorating, preventing, or treating a filovirus infection in a subject in need thereof.

17. The use of claim 16, wherein the filovirus infection is a Marburg virus infection or an Ebola virus infection.

18. An isolated nucleic acid molecule encoding the monoclonal antibody or antigen-binding portion thereof of any one of claims 1-8.

19. An isolated nucleic acid molecule encoding (a) the immunoglobulin light chain variable region, (b) the immunoglobulin heavy chain variable region, or (c) the immunoglobulin light chain and heavy chain variable regions of the monoclonal antibody or antigen-binding portion thereof of any one of claims 1-8.

20. The isolated nucleic acid molecule of claim 18 or 19, wherein the nucleic acid molecule comprises one or more nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.

21. The isolated nucleic acid molecule of claim 18 or 19, wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:202 or 203.

22. An expression vector comprising a nucleic acid segment encoding (a) the immunoglobulin light chain variable region, (b) the immunoglobulin heavy chain variable region, or (c) the immunoglobulin light and heavy chain variable regions

of the monoclonal antibody or antigen-binding portion thereof of any one of claims 1-8, wherein the nucleic acid segment is operatively linked to regulatory sequences suitable for expression of the nucleic acid segment in a host cell.

23. The expression vector of claim 22, wherein the nucleic acid segment comprises one or more nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.

24. The expression vector of claim 23, wherein the nucleic acid segment comprises the nucleotide sequence of SEQ ID NO:202 or 203.

25. A recombinant host cell comprising the expression vector of any one of claims 22-24.

26. The recombinant host cell of claim 25, wherein the cell is a bacterial, eukaryotic, or mammalian cell.

27. The recombinant host cell of claim 25 or 26, wherein the cell is a COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, HepG2, SP2/0, HeLa, myeloma, or lymphoma cell.

28. A method for producing a filovirus-binding monoclonal antibody or antigen-binding portion thereof, wherein the method comprises culturing a recombinant host cell comprising the expression vector of any one of claims 22-24 under conditions whereby the nucleic acid segment is expressed, thereby producing the filovirus-binding monoclonal antibody or antigen-binding portion.

29. The method of claim 28, further comprising recovering the filovirus-binding monoclonal antibody or antigen-binding portion thereof.

30. A method for detecting a filovirus glycoprotein in a sample, the method comprising contacting the sample with the antibody or antigen-binding portion thereof of any one of claims 1-8.

31. The method of claim 30, wherein the sample is a cell, tissue, or biological fluid from a subject suspected of having or at risk of a filovirus infection.

32. The method of claim 30 or 31, wherein the filovirus glycoprotein is a Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus, or Reston virus glycoprotein.

33. The monoclonal antibody or antigen-binding portion thereof of any one of claims 1-8 or the pharmaceutical composition of any one of claims 9-15 for use in therapy.

34. The monoclonal antibody or antigen-binding portion thereof of any one of claims 1-8 or the pharmaceutical composition of any one of claims 9-15 for use in ameliorating, preventing, or treating a filovirus infection in a subject in need thereof.

35. The monoclonal antibody or antigen-binding portion thereof or the pharmaceutical composition for use in claim 34, wherein the filovirus infection is a Marburg virus infection or an Ebola virus infection.